Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Breast Care (Basel, Switzerland)|June 13, 2025
Online Training to Increase Genetic and Risk Literacy in Physicians Counseling Breast and Ovarian Cancer Patients for Genetic TestingKerstin Rhiem, Clara Breidenbach, Anke Waha, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|September 14, 2016
The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancerGuido Neidhardt, Alexandra Becker, Jan Hauke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2025
Reclassification of ATM Missense Variants of Uncertain Significance by Integrating Results from Systematic Functional Assays into an ACMG Points-Based FrameworkHelmut Hanenberg, Fan Zhang, Nikita Malev, et al.
Human Mutation|September 15, 2018
Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trialKonstantin Weber-Lassalle, Philipp Harter, Jan Hauke, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 7, 2023
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trialFlorian Heitz, Christian Marth, Stéphanie Henry, et al.
JCO Precision Oncology|June 12, 2026
Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 StudyMohamad Kayali, Eric Hahnen, Alexander Burges, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 5, 2010
Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutationsMaria I Behrens, Norbert Brüggemann, Pedro Chana, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2025
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slidesFrederik Marmé, Eva I Krieghoff-Henning, Lennard Kiehl, et al.
Journal of the National Cancer Institute|December 28, 2021
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian CancerKonstantin Weber-Lassalle, Corinna Ernst, Alexander Reuss, et al.
Journal of Medical Genetics|December 4, 2020
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in BRCA1/2: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Philipp Harter, Corinna Ernst, et al.
Pageof 8